3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Other solid neoplasm
3
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Dermatologic
1
Conditions
Neuroectodermal Tumors, Primitive
1
Gastrointestinal Stromal Tumors
1
Interventions
Temozolomide
62
Cyclophosphamide
59
Radiotherapy
47
Doxorubicin
36
Filgrastim
26
Irinotecan
24
Radiation
23
Gemcitabine
23
fludarabine
22
Magnetic Resonance Spectroscopy
20
Imatinib Mesylate
19
Etoposide
18
pembrolizumab
16
Cisplatin
15
Carboplatin
15
Biopsy
15
Bevacizumab
15
Specimen Handling
14
fludarabine phosphate
12
Nivolumab
12
Leucovorin
12
Ipilimumab
12
Granulocyte Colony-Stimulating Factor
12
Chemotherapy, Adjuvant
12
pazopanib
11
Vincristine
11
Ifosfamide
11
Melphalan
10
Erlotinib Hydrochloride
10
Docetaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
TH 302
×
Sarcoma
×
Clear all
NCT01381822
2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1
Unknown
58 enrolled